176 related articles for article (PubMed ID: 32803288)
1. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
[TBL] [Abstract][Full Text] [Related]
2. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
3. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
[TBL] [Abstract][Full Text] [Related]
4. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
5. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
Nemoz B; Ternant D; Bailly S; Gautier-Veyret E; Jourdil JF; Bonaz B; Stanke-Labesque F
Br J Clin Pharmacol; 2019 Apr; 85(4):722-728. PubMed ID: 30575085
[TBL] [Abstract][Full Text] [Related]
6. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
Roblin X; Nancey S; Papamichael K; Duru G; Flamand M; Kwiatek S; Cheifetz A; Fabien N; Barrau M; Paul S
J Crohns Colitis; 2024 May; 18(5):679-685. PubMed ID: 37934041
[TBL] [Abstract][Full Text] [Related]
7. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
[TBL] [Abstract][Full Text] [Related]
8. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
[TBL] [Abstract][Full Text] [Related]
9. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Choe YH
Gut Liver; 2019 Sep; 13(5):541-548. PubMed ID: 30970435
[TBL] [Abstract][Full Text] [Related]
10. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
[TBL] [Abstract][Full Text] [Related]
12. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
13. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
14. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
15. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
[TBL] [Abstract][Full Text] [Related]
16. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
17. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Lee JH; Choe YH
Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
[TBL] [Abstract][Full Text] [Related]
18. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
19. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):847-853. PubMed ID: 30633108
[TBL] [Abstract][Full Text] [Related]
20. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
Levartovsky A; Ungar B; Yavzori M; Picard O; Fudim E; Eliakim R; Paul S; Roblin X; Ben-Horin S; Kopylov U
Int J Colorectal Dis; 2020 Jun; 35(6):1141-1148. PubMed ID: 32296932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
